About Oasis Diagnostics
Oasis Diagnostics is a Healthcare company based in Vancouver (United States) founded in 2002. It operates as a non-invasive saliva-based diagnostics and collection tools are developed and marketed. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its competitors include ArcherDX, Qiagen, Devyser, Third Wave Technologies and DxTerity and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Oasis Diagnostics is engaged in development and marketing of non-invasive saliva-based technology for rapid testing, sample collection, and molecular diagnostics DNA, RNA and proteins. Its products Versi SAL is a standardized whole saliva collection tool, UltraSal-2 for large volume oral specimen collection and SuperSAM saliva collection device for universal saliva collection purposes. The company is focused on developing tools for specific applications in the areas of stress, dehydration, drugs of abuse, infectious diseases (including HIV and tuberculosis), steroid hormones, oncology, Alzheimers disease and Parkinsons disease.
- Headquarters Vancouver, United States
- SectorsHealthcare
- Email••••••••
- Website 4saliva.com
- Social LinkedIn X Facebook YouTube
- InvestorsMeridian Bioscience
& 4 more
Apps and channels of Oasis Diagnostics
its YouTube channel 4saliva has 18 subscribers.
Funding Insights of Oasis Diagnostics
- Total Rounds 6
- First Round $50,000
(Apr 2009)
- Investors Count 5
All 6 funding rounds of Oasis Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | – | Grant | – | – | |
| Nov 2015 | – | Private Equity Round | – | – | |
| Jan 2014 | – | Grant | – | – | |
| Aug 2013 | $1.3M | Grant | – | – | |
| Jul 2012 | – | Grant | – | – | |
| Apr 2009 | $50,000 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Oasis Diagnostics
Oasis Diagnostics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Meridian Bioscience, NIH and The Michael J. Fox Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | ghitfund.org | - | |
- | – | zinosociety.com | - | |
Molecular diagnostic device and kits | 1976 | meridianbioscience.com | Ohio, United States | |
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Oasis Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Oasis Diagnostics
3 dated milestones of Oasis Diagnostics across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Oasis Diagnostics is founded.
- Funding First funding round of $50K.
- Funding Latest funding round, Grant,.
Competitors of Oasis Diagnostics
Oasis Diagnostics has 10 listed competitors in our database, 8 of them funded. They include ArcherDX, Qiagen, Devyser, Third Wave Technologies and DxTerity, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| qiagen.com | 1984 | Hilden, Germany | – | 104 | Products and reagents for molecular diagnostic assays are supplied. | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders | |
| twt.com | 1993 | Xiamen, China | $19.3M | – | Molecular diagnostic devices and reagents are developed and marketed. | |
| dxterity.com | 2006 | Los Angeles, United States | $3.75M | – | Provider of a direct-to-consumer, non-clinical genetic tests | |
| dhiusa.com | 1983 | Athens, United States | $10M | 1,103 | Molecular diagnostic kits for infectious diseases are developed and manufactured. | |
| predictimmune.com | 2017 | Cambridge, United Kingdom | $18.32M | 15 | Tools for diagnosing immune-mediated inflammatory diseases are developed. | |
| gen-probe.com | 1996 | San Diego, United States | – | – | Provides clinical diagnostics, blood screening, and research products. | |
| kiomedpharma.com | 2012 | Herstal, Belgium | $6.73M | 20 | Bio-polymer chitosan products are developed for medical uses. | |
| thunder-bio.com | 2018 | Jiaxing, China | $15.47M | – | Microfluidic technology is developed for diagnostic and research applications. |
Detailed competitors of Oasis Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Oasis Diagnostics
The website of Oasis Diagnostics (4saliva.com) receives about 3.4K visits a month.
- Monthly visits3.4K
▲ 19% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Oasis Diagnostics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Oasis Diagnostics
Oasis Diagnostics was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Oasis Diagnostics is headquartered in Vancouver, United States. It is registered at Vancouver, Washington, United States.
Oasis Diagnostics is engaged in development and marketing of non-invasive saliva-based technology for rapid testing, sample collection, and molecular diagnostics DNA, RNA and proteins. Its products Versi SAL is a standardized whole saliva collection tool, UltraSal-2 for large volume oral specimen collection and SuperSAM saliva collection device for universal saliva collection purposes. The company is focused on developing tools for specific applications in the areas of stress, dehydration, drugs of abuse, infectious diseases (including HIV and tuberculosis), steroid hormones, oncology, Alzheimers disease and Parkinsons disease.
Oasis Diagnostics has 5 investors. Key investors include Meridian Bioscience, NIH, The Michael J. Fox Foundation, GHIT Fund, and ZINO Society.